Background Left ventricular hypertrophy (LVH) is an independent predictor for cardiovascular events in chronic kidney disease (CKD). Objectives To find relationship between left ventricular hypertrophy and CKD stages during predialysis period and assess risk factors in CKD patients for left ventricular hypertrophy. Methods This cross-sectional study of 125 participant with CKD was conducted at Shar Teaching Hospital of Nephrology department, Sulaimani, Iraq. Left ventricular mass index (LVMI) was measured by using two-dimensional echocardiogram in the left decubitus position. LVH was labeled when the left ventricular mass index was >115 g/m² in men, and >95 g/m² in women on echocardiogram. We analyzed the baseline characteristic in 125 patients with chronic kidney diseaase. All patients underwent laboratory investigations which included serum creatinine, complete blood count, serum calcium, phosphate, intact parathyroid hormone, high density lipoprotein cholesterol HDL-C, low density lipoprotein LDL-C, triglyceride, and total cholesterol with urine albumin to creatinine ratio. Results The mean age was 55.27± 14.51 years(male 60.0%, female 40.0%), and the prevalence of LVH was 68.0%, and it was increased with progressive decline in estimated glomerular filtration rate(eGFR) (P =0.005). independent risk factors for LVH were anemia (P =0.000), systolic and diastolic BP (P =0.000; P =0.001 respectively), intact PTH (P =0.038), body mass index BMI(P =0.045), serum calcium (P =0.003),serum phosphate (P =0.001) and majority of lipid profiles. Conclusion There was a high prevalence of LVH in the CKD patients and it was increased with progressively decline in renal function. There was a significant association between systolic and diastolic BP, intact PTH, hemoglobin level, BMI, and minerals with LVH in CKD patients.
Vitamin D insufficiency is common in patients suffering from end-stage renal disease (ESRD). In contrast, vitamin D supplementation could improve the status of ESRD patients (ESRDP). However, this effect's molecular mechanism is not fully understood. Therefore, this study aimed to assess vitamin D supplementation's impact on inflammation and oxidative signaling pathways in ESRDP. 104 ESRDP were divided into placebo (53) and vitamin D (51) groups. They were also categorized into four subgroups based on the severity of vitamin D deficiency. The dose of vitamin D3 (0.25-0.5mg/day) supplementation was determined based on plasma levels of calcium and parathyroid hormone (PTH). Vitamin D supplementation was performed for eight weeks. Serum levels of calcium, phosphorus, PTH, albumin, creatinine, ALP, and glomerular filtration along with antioxidant enzymes, malondialdehyde, and pro-inflammatory factors were measured. Moreover, the Nrf2 and NF-ĸB expression was evaluated in whole blood. According to the results, vitamin D supplementation improved the status of patients with ESRD significantly as compared with the placebo group (p<0.05). In addition, the expression of NF-ĸB and the serum levels of pro-inflammatory factors and malondialdehyde were significantly reduced. Finally, the expression of Nrf-2 and the serum of antioxidant enzymes were raised in the vitamin D group as compared with the placebo group (p<0.05). Vitamin D reduces clinical and metabolic symptoms in ESRDP by modulating gene expression (in oxidative stress and inflammation).
Background Thalassemia major is one of the most inherited disorders in the Middle East; it has many complications related to iron overload and hepatitis viral transmission; complication of iron overload has destructing effect on many organ systems including liver; heart; pancreas; and lung. In the lung lead to pulmonary arterial hypertension which is defined as pulmonary artery systolic pressure ≥25mmHg during rest. Objectives To detect the prevalence of pulmonary hypertension in patients with thalassemia major and how supportive measures affecting outcome of it. Patients and Methods A cross sectional study undertaken in Shaheid Hemn Teaching hospital, center for internal medicine diseases with collaboration of thalassemia center inside the hospital; 100 thalassemia major patients who are diagnosed previously by hemoglobin electrophoresis without any other comorbidity taken as a sample and echocardiography done using Phillips CX50 machine of 2009 model; the data then collected and using SPSS v23 for analyzing data. Results Study show 53% of thalassemia major has evidence of increased pulmonary artery pressure and only 1% has clinically significant pressure; splenectomy show high risk factor for occurrence of pulmonary hypertension but other supportive measures has no obstacle effect in its occurrence. Conclusion Most thalassemia major patients have evidence of pulmonary hypertension at least mild one; and putting splenectomy as a last line of managing them is recommended.
Background Global increase in the incidence of end-stage renal disease has necessitated the performance of kidney transplantation for many patients. To minimize the possibility of renal allograft failure and maintain graft function. Kidney transplant recipients are typically given immunosuppressive drugs such as tacrolimus and Cyclosporine in combination with other drugs. Objectives The present study was carried out to compare the effectiveness of tacrolimus versus Cyclosporine. Patients and Methods The present clinical non-randomized and non-controlled study was conducted on 201 kidney transplant patients in Shar teaching Hospital in Sulaimani, Kurdistan region-Iraq, from April 2020 to April 2021. The patients had received tacrolimus and Cyclosporine as immunosuppression drugs. Required data were collected from the patients through their hospital records and direct interviews with them. The collected data were analyzed through Statistical Package for Social Science (version 22.0). Results Most patients (60.7%) were aged 19-45 and males (70.6%). Most of them did not know the cause of chronic kidney failure (41.3%), focal segmental glomerulosclerosis in 14.4%, and diabetes mellitus in 12.4%. Most of the donors were non-related (90.5%). Induction treatment was anti-thymocyte globulin for most of them (76.6%), and treatment after transplant, mycophenolate mofetil, Cyclosporine and prednisolone in 75% of them. Acute cellular rejection was the most frequent complication after the transplant (23.4%). Tremor and new onset of diabetes were the most frequent side effects of tacrolimus; however, hirsutism, hyperkalemia, acne, hypertension, and hyperlipidemia are the most frequent side effects Cyclosporine. More patients on Tacrolimus than Cyclosporine developed new onset of diabetes (7.5%). However, serum uric acid (p<0.001), serum cholesterol (p<0.001), and serum triglyceride (p=0.01) levels elevate more with Cyclosporine group patients. Moreover, drug change has a significant association with haemoglobin level (HGB) (p<0.001) and serum triglyceride (p<0.001) in those group drug was changed to tacrolimus. Conclusion Similar rejection was obtained by using Tacrolimus and Cyclosporine within the first year after kidney transplant in low immunological risk patients; however, acute cellular rejection was less with the TAC group. It is less expensive than Cyclosporine in our region, but Cyclosporine is more available in the hospital.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.